AR and metastatic neoplasm: Current treatments for recurrent or metastatic disease include targeting androgen receptor (AR) signaling through the use of antiandrogens, such as bicalutamide, and drugs that prevent the production of androgens in the testicles and adrenal glands, such as gonadotropin-releasing hormone agonists and ketoconazole [3].